CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 622 enrolled
Drug / intervention
Ceftaroline fosamil for Injection +2 moredrug
Likely dose
Ceftaroline fosamil for Injection 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00509106
NCT00509106Phase 3Completed

A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Ceftriaxone in the Treatment of Adult Subjects With Community-Acquired Pneumonia

Forest Laboratories·interventional·Posted Jul 31, 2007·Updated Mar 14, 2017

In Brief

A Phase 3 clinical trial evaluating Ceftaroline fosamil for Injection, Ceftriaxone, and 1 other intervention for Bacterial Pneumonia. Completed, enrolled 622 participants across 134 sites in 15 countries.

Detailed Summary

The purpose of the study is to determine if the antibiotic ceftaroline is safe and effective in the treatment of community-acquired pneumonia in adults.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesArgentina, Austria, Bulgaria, Chile, Germany, Hungary, India, Latvia, Mexico, Peru, Poland, Romania, Russia, Ukraine, United States
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 31, 2007
Enrollment StartJul 1, 2007
Primary CompletionAug 1, 2008
Study CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 18.9 years ago

Interventions

Ceftaroline fosamil for Injectiondrug

2 consecutive, 300 mg dose parenteral infused over 30 minutes, every 12 hours for 5 to 7 days

Ceftriaxonedrug

1 g dose parenteral infused over 30 minutes, every 24 hours for 5 to 7 days

Placebodrug

Subjects randomized to receive ceftriaxone will receive ceftriaxone at a dose of 1 g infused over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h). Twelve hours after each dose of ceftriaxone and saline placebo (ie, between ceftriaxone doses), subjects in this group will receive two consecutive saline placebo infusions, each infused over 30 minutes q24h. The ceftriaxone and saline placebo infusions will correspond to the q12h infusions of ceftaroline, thereby maintaining the blind